EXHIBIT B

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS
AB A review with 24 refs. Ziprasidone is a novel antipsychotic drug. It has
high affinity for serotonin 5-HT2 and dopamine D2
receptors in vitro, with an 11-fold higher affinity for 5-HT2
than for D2 receptors, suggestive of a low potential for inducing motor
disturbance [including extrapyramidal symptoms (EPS)]. The effects of
ziprasidone in receptor binding studies reflected its in vitro pharmacol.,
with more potent effects against 5-HT2 receptor-than against D2
receptor-mediated behavior. Because ziprasidone inhibits serotonin
(5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine) reuptake,
it may have anxiolytic and antidepressant effects. Data from phase II and
III clin. trials have shown ziprasidone to be effective in reducing the
pos. and neg. symptoms of, and depression assocd. with, schizophrenia, and
in reducing anxiety in patients about to undergo dental surgery.
Ziprasidone was generally well tolerated in phase II and III clin. trials,
with somnolence and nausea being the most frequently reported adverse
events in placebo-controlled studies. Motor disturbances, including EPS,
were infrequently obsd.
AN 1997:593623 CAPLUS
DN 127:242699
TI Ziprasidone
AU Davis, Rick; Markham, Anthony
CS Adis International Limited, Auckland, N. Z.
SO CNS Drugs (1997), 8(2), 153-159
CODEN: CNDREF; ISSN: 1172-7047
PB Adis
DT Journal; General Review
LA English
AB A review with 24 refs. Ziprasidone is a novel antipsychotic drug. It has
high affinity for serotonin 5-HT2 and dopamine D2
receptors in vitro, with an 11-fold higher affinity for 5-HT2
than for D2 receptors, suggestive of a low potential for inducing motor
disturbance [including extrapyramidal symptoms (EPS)]. The effects of
ziprasidone in receptor binding studies reflected its in vitro pharmacol.,
with more potent effects against 5-HT2 receptor-than against D2
receptor-mediated behavior. Because ziprasidone inhibits serotonin
(5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine) reuptake,
it may have anxiolytic and antidepressant effects. Data from phase II and
III clin. trials have shown ziprasidone to be effective in reducing the
pos. and neg. symptoms of, and depression assocd. with, schizophrenia, and
in reducing anxiety in patients about to undergo dental surgery.
Ziprasidone was generally well tolerated in phase II and III clin. trials,
with somnolence and nausea being the most frequently reported adverse
events in placebo-controlled studies. Motor disturbances, including EPS,
were infrequently obsd.
IT 146939-27-7, Ziprasidone
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(ziprasidone for psychotic disorders)